Author: Chunyun Sun; Long Chen; Ji Yang; Chunxia Luo; Yanjing Zhang; Jing Li; Jiahui Yang; Jie Zhang; Liangzhi Xie
Title: SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development Document date: 2020_2_20
ID: nhq0oq8y_36
Snippet: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.02.16.951723 doi: bioRxiv preprint cell receptors to initiate infection. Both SARS-CoV and SARS-CoV viruses use human ACE2 for cell entry 10 . Due to the nature of RNA virus' rapid mutation rates, changes in the S-protein's amino acid sequence, especially in the RBD's receptor binding motif, could have significant impact on virus infectivity.....
Document: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.02.16.951723 doi: bioRxiv preprint cell receptors to initiate infection. Both SARS-CoV and SARS-CoV viruses use human ACE2 for cell entry 10 . Due to the nature of RNA virus' rapid mutation rates, changes in the S-protein's amino acid sequence, especially in the RBD's receptor binding motif, could have significant impact on virus infectivity, pathogenicity, transmissibility, and cross-protection from previous coronavirus infection, as well as therapeutic antibody and prophylactic vaccine development. Hence, understanding the differences between SARS-CoV and SARS-CoV-2 and their implications may offer significant scientific and practical value.
Search related documents:
Co phrase search for related documents- amino acid and cell entry: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
- amino acid and coronavirus infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- amino acid and cross protection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- amino acid and infection initiate: 1, 2, 3
- amino acid and prophylactic vaccine: 1, 2, 3, 4, 5
- amino acid and rapid mutation: 1, 2, 3
- amino acid and rapid mutation rate: 1
- amino acid and RBD receptor bind motif: 1
- amino acid and receptor bind motif: 1
- amino acid and RNA virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
- amino acid and SARS CoV virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
- amino acid and significant impact: 1, 2, 3, 4, 5, 6, 7, 8
- amino acid and therapeutic antibody: 1, 2, 3, 4, 5
- amino acid and virus infectivity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38
- amino acid sequence and bind motif: 1
- amino acid sequence and cell entry: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- amino acid sequence and coronavirus infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- amino acid sequence and cross protection: 1, 2, 3
- amino acid sequence and infection initiate: 1
Co phrase search for related documents, hyperlinks ordered by date